Share Price | CVRx, Inc. Stock Analysis & Recommendation

Q: What does CVRx, Inc. do?

Overview:CVRx, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 12 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) Market cap: USD 147.57 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.76 Return on Equity: -74.32% Price to Book: 2.13 Contact Details:Registrar Address: Not available.

Q: Should I buy, sell or hold CVRx, Inc.?

Based on the current situation with CVRx, Inc., it would be advisable to consider selling your shares. The company has shown flat results recently, and while interest has grown significantly, the overall financial health appears concerning due to negative EBITDA. Additionally, the stock has not generated any return over the past year, with profits only slightly increasing. Given these factors, holding onto the stock may pose unnecessary risks.

Q: Is CVRx, Inc. technically bullish or bearish?

As of 6 August 2025, the technical trend for CVRx, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators supporting this view including a bearish signal from the daily moving averages and a bearish monthly MACD. The weekly MACD and Bollinger Bands show mildly bullish signals, but these are countered by the overall bearish monthly indicators. Additionally, the Dow Theory and OBV indicate a mildly bearish stance on both weekly and monthly time frames. In terms of performance, CVRx has underperformed the S&P 500 across multiple periods, with a year-to-date return of -43.41% compared to the S&P 500's 12.22%, and a one-year return of -17.49% versus 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

976.16 k

Shareholding (Sep 2025)

FII

4.26%

Held by 33 FIIs

DII

59.33%

Held by 15 DIIs

Promoter

23.54%

How big is CVRx, Inc.?

22-Jun-2025

As of Jun 18, CVRx, Inc. has a market capitalization of 147.57 million, with net sales of 52.87 million and a consolidated net profit of -51.55 million over the last four quarters. Shareholder's funds total 71.06 million, and total assets are reported at 133.41 million.

View full answer

What does CVRx, Inc. do?

22-Jun-2025

CVRx, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $12 million and a net loss of $14 million as of March 2025, with a market cap of $147.57 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -74.32%.

View full answer

Should I buy, sell or hold CVRx, Inc.?

22-Jun-2025

Is CVRx, Inc. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, CVRx, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and monthly MACD, despite some mildly bullish signals from weekly indicators, and has significantly underperformed the S&P 500 with a year-to-date return of -43.41%.

View full answer

Compare CVRx, Inc. with Similar Stocks

Utah Medical Products, Inc.Tactile Systems Technology, Inc.CareDx, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Jun 25

INTEREST(HY) At USD 2.93 MM has Grown at 52.68%
ROCE(HY) Lowest at -92.33%
OPERATING PROFIT(Q) Lowest at USD -14.18 MM

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 158 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.74

Return on Equity

-108.26%

Price to Book

3.29

Revenue and Profits:

Net Sales:

14 Million

(Quarterly Results - Jun 2025)

Net Profit:

-15 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-35.31%

6 Months

-46.25%

1 Year

-19.93%

2 Years

-50.64%

3 Years

8.62%

4 Years

0.0%

5 Years

0.0%

CVRx, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

56.67%

EBIT Growth (5y)

-208.60%

EBIT to Interest (avg)

-23.39

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.76

Sales to Capital Employed (avg)

0.44

Tax Ratio

0.02%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

70.09%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.47

EV to EBIT

-2.33

EV to EBITDA

-2.36

EV to Capital Employed

7.23

EV to Sales

2.23

PEG Ratio

Dividend Yield

ROCE (Latest)

-310.75%

ROE (Latest)

-74.32%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 29 Schemes (12.87%)

Foreign Institutions

Held by 33 Foreign Institutions (4.26%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.25% vs 24.21% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -5.00% vs -19.66% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13.60",
          "val2": "11.80",
          "chgp": "15.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.20",
          "val2": "-13.80",
          "chgp": "-2.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "1.00",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.70",
          "val2": "-14.00",
          "chgp": "-5.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,057.90%",
          "val2": "-1,183.50%",
          "chgp": "12.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.53% vs 74.67% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -45.63% vs 0.48% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "51.30",
          "val2": "39.30",
          "chgp": "30.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-58.90",
          "val2": "-42.60",
          "chgp": "-38.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.40",
          "val2": "1.80",
          "chgp": "144.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-60.00",
          "val2": "-41.20",
          "chgp": "-45.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,159.80%",
          "val2": "-1,096.90%",
          "chgp": "-6.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

13.60

11.80

15.25%

Operating Profit (PBDIT) excl Other Income

-14.20

-13.80

-2.90%

Interest

1.50

1.00

50.00%

Exceptional Items

0.00

Consolidate Net Profit

-14.70

-14.00

-5.00%

Operating Profit Margin (Excl OI)

-1,057.90%

-1,183.50%

12.56%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 15.25% vs 24.21% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -5.00% vs -19.66% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

51.30

39.30

30.53%

Operating Profit (PBDIT) excl Other Income

-58.90

-42.60

-38.26%

Interest

4.40

1.80

144.44%

Exceptional Items

0.00

Consolidate Net Profit

-60.00

-41.20

-45.63%

Operating Profit Margin (Excl OI)

-1,159.80%

-1,096.90%

-6.29%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 30.53% vs 74.67% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -45.63% vs 0.48% in Dec 2023

All Annual Results

Company CV

About CVRx, Inc.

CVRx, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

CVRx, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is CVRx, Inc.?

Watch in Real-Time

What does CVRx, Inc. do?

Should I buy, sell or hold CVRx, Inc.?

Is CVRx, Inc. technically bullish or bearish?

Compare CVRx, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Flat results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About CVRx, Inc.

Company Coordinates